array(40) {
  [0]=>
  string(4) "8123"
  ["article_id"]=>
  string(4) "8123"
  [1]=>
  string(92) "BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930"
  ["article_title"]=>
  string(92) "BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930"
  [2]=>
  string(150) "BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to r"
  ["short_description"]=>
  string(150) "BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to r"
  [3]=>
  string(634) "
BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to report data from the proof of 
&#nl
The post BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(634) "
BCX9930 is an oral Factor D inhibitor discovered and developed by BioCryst for the treatment of complement-mediated diseases. The company expects to report data from the proof of 
&#nl
The post BioCryst begins proof of concept trial in PNH patients with oral Factor D inhibitor, BCX9930 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(144) "https://www.pharmaceutical-business-review.com/news/biocryst-begins-proof-of-concept-trial-in-pnh-patients-with-oral-factor-d-inhibitor-bcx9930/"
  ["blog_url"]=>
  string(144) "https://www.pharmaceutical-business-review.com/news/biocryst-begins-proof-of-concept-trial-in-pnh-patients-with-oral-factor-d-inhibitor-bcx9930/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8124"
  ["article_id"]=>
  string(4) "8124"
  [1]=>
  string(92) "Urovant Sciences announces US FDA acceptance of NDA for Vibegron to treat overactive bladder"
  ["article_title"]=>
  string(92) "Urovant Sciences announces US FDA acceptance of NDA for Vibegron to treat overactive bladder"
  [2]=>
  string(150) "The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020. In addition, the FDA has communicated that they are"
  ["short_description"]=>
  string(150) "The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020. In addition, the FDA has communicated that they are"
  [3]=>
  string(611) "
The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020. In addition, the FDA has communicated that they are not 
&#nl
The post Urovant Sciences announces US FDA acceptance of NDA for Vibegron to treat overactive bladder appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(611) "
The NDA has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2020. In addition, the FDA has communicated that they are not 
&#nl
The post Urovant Sciences announces US FDA acceptance of NDA for Vibegron to treat overactive bladder appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/urovant-sciences-announces-us-fda-acceptance-of-nda-for-vibegron-to-treat-overactive-bladder/"
  ["blog_url"]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/urovant-sciences-announces-us-fda-acceptance-of-nda-for-vibegron-to-treat-overactive-bladder/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8125"
  ["article_id"]=>
  string(4) "8125"
  [1]=>
  string(67) "Zydus secures DCGI approval for Saroglitazar to treat liver disease"
  ["article_title"]=>
  string(67) "Zydus secures DCGI approval for Saroglitazar to treat liver disease"
  [2]=>
  string(150) "NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is cl"
  ["short_description"]=>
  string(150) "NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is cl"
  [3]=>
  string(531) "
NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is claimed to be the 
&#nl
The post Zydus secures DCGI approval for Saroglitazar to treat liver disease appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(531) "
NASH, a progressive disease of the liver, commences with fat accumulation in the liver and may lead to cirrhosis and liver failure. Saroglitazar is claimed to be the 
&#nl
The post Zydus secures DCGI approval for Saroglitazar to treat liver disease appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/zydus-cirrhotic-nash-india/"
  ["blog_url"]=>
  string(79) "https://www.pharmaceutical-business-review.com/news/zydus-cirrhotic-nash-india/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8126"
  ["article_id"]=>
  string(4) "8126"
  [1]=>
  string(59) "Amunix raises $73m in Series A financing led by Omega Funds"
  ["article_title"]=>
  string(59) "Amunix raises $73m in Series A financing led by Omega Funds"
  [2]=>
  string(150) "Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital,"
  ["short_description"]=>
  string(150) "Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital,"
  [3]=>
  string(609) "
Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock, 
&#nl
The post Amunix raises $73m in Series A financing led by Omega Funds appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(609) "
Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, Casdin Capital, Two River, Venrock, 
&#nl
The post Amunix raises $73m in Series A financing led by Omega Funds appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(111) "https://www.pharmaceutical-business-review.com/news/amunix-raises-73m-in-series-a-financing-led-by-omega-funds/"
  ["blog_url"]=>
  string(111) "https://www.pharmaceutical-business-review.com/news/amunix-raises-73m-in-series-a-financing-led-by-omega-funds/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8127"
  ["article_id"]=>
  string(4) "8127"
  [1]=>
  string(135) "Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents"
  ["article_title"]=>
  string(135) "Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents"
  [2]=>
  string(150) "Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum,"
  ["short_description"]=>
  string(150) "Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum,"
  [3]=>
  string(727) "
Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most 
&#nl
The post Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(727) "
Specifically, they identified novel dual inhibitors of plasmepsins IX and X (PMIX and PMX), two proteases that are essential to Plasmodium falciparum, the predominant cause of the most 
&#nl
The post Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research discover novel class of candidate anti malaria agents appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(188) "https://www.pharmaceutical-business-review.com/news/scientists-from-merck-and-the-walter-and-eliza-hall-institute-of-medical-research-discover-novel-class-of-candidate-anti-malaria-agents/"
  ["blog_url"]=>
  string(188) "https://www.pharmaceutical-business-review.com/news/scientists-from-merck-and-the-walter-and-eliza-hall-institute-of-medical-research-discover-novel-class-of-candidate-anti-malaria-agents/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-11 16:23:53"
  ["create_at"]=>
  string(19) "2020-03-11 16:23:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8255"
  ["article_id"]=>
  string(4) "8255"
  [1]=>
  string(75) "Bristol Myers Squibb gets FDA nod for Opdivo + Yervoy to treat liver cancer"
  ["article_title"]=>
  string(75) "Bristol Myers Squibb gets FDA nod for Opdivo + Yervoy to treat liver cancer"
  [2]=>
  string(155) "The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate "
  ["short_description"]=>
  string(155) "The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate "
  [3]=>
  string(548) "
The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate -040 trial. Around 
&#nl
The post Bristol Myers Squibb gets FDA nod for Opdivo + Yervoy to treat liver cancer appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(548) "
The FDA accelerated approval was based on Opdivo + Yervoy’s overall response rate and duration of response in the cohort of the phase 1/2 CheckMate -040 trial. Around 
&#nl
The post Bristol Myers Squibb gets FDA nod for Opdivo + Yervoy to treat liver cancer appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/bristol-myers-squibb-opdivo/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/bristol-myers-squibb-opdivo/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:03"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:03"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8256"
  ["article_id"]=>
  string(4) "8256"
  [1]=>
  string(64) "TOURMALINE-MM2 study on NINLARO fails to deliver desired results"
  ["article_title"]=>
  string(64) "TOURMALINE-MM2 study on NINLARO fails to deliver desired results"
  [2]=>
  string(150) "The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. N"
  ["short_description"]=>
  string(150) "The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. N"
  [3]=>
  string(560) "
The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. NINLARO is an oral proteasome inhibitor, which 
&#nl
The post TOURMALINE-MM2 study on NINLARO fails to deliver desired results appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(560) "
The late-stage TOURMALINE-MM2 trial featured 705 adult patients who are newly diagnosed with multiple myeloma and are not candidates for transplant. NINLARO is an oral proteasome inhibitor, which 
&#nl
The post TOURMALINE-MM2 study on NINLARO fails to deliver desired results appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/tourmaline-mm2-study-results/"
  ["blog_url"]=>
  string(81) "https://www.pharmaceutical-business-review.com/news/tourmaline-mm2-study-results/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:03"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:03"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8257"
  ["article_id"]=>
  string(4) "8257"
  [1]=>
  string(119) "InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects"
  ["article_title"]=>
  string(119) "InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects"
  [2]=>
  string(150) "INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has cond"
  ["short_description"]=>
  string(150) "INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has cond"
  [3]=>
  string(712) "
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has conducted preclinical pharmacology studies that suggest 
&#nl
The post InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(712) "
INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. InMed has conducted preclinical pharmacology studies that suggest 
&#nl
The post InMed Pharmaceuticals announces completed enrollment in phase 1 clinical trial of INM-755 CBN Cream in healthy subjects appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(172) "https://www.pharmaceutical-business-review.com/news/inmed-pharmaceuticals-announces-completed-enrollment-in-phase-1-clinical-trial-of-inm-755-cbn-cream-in-healthy-subjects/"
  ["blog_url"]=>
  string(172) "https://www.pharmaceutical-business-review.com/news/inmed-pharmaceuticals-announces-completed-enrollment-in-phase-1-clinical-trial-of-inm-755-cbn-cream-in-healthy-subjects/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:03"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:03"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8258"
  ["article_id"]=>
  string(4) "8258"
  [1]=>
  string(92) "Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies"
  ["article_title"]=>
  string(92) "Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies"
  [2]=>
  string(150) "IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neurobla"
  ["short_description"]=>
  string(150) "IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neurobla"
  [3]=>
  string(644) "
IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT 
&#nl
The post Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(644) "
IP Group, Baylor College of Medicine and Schroeder Adveq are investing to support two phase 1 studies: GINAKIT 2 (autologous CAR-NKT cells in neuroblastoma) and ANCHOR (allogeneic CAR-NKT 
&#nl
The post Kuur Therapeutics launches to develop and commercialise off-the-shelf CAR-NKT cell therapies appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/kuur-therapeutics-launches-to-develop-and-commercialise-off-the-shelf-car-nkt-cell-therapies/"
  ["blog_url"]=>
  string(145) "https://www.pharmaceutical-business-review.com/news/kuur-therapeutics-launches-to-develop-and-commercialise-off-the-shelf-car-nkt-cell-therapies/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-12 15:56:03"
  ["create_at"]=>
  string(19) "2020-03-12 15:56:03"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8384"
  ["article_id"]=>
  string(4) "8384"
  [1]=>
  string(72) "Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial"
  ["article_title"]=>
  string(72) "Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial"
  [2]=>
  string(150) "Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setti"
  ["short_description"]=>
  string(150) "Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setti"
  [3]=>
  string(555) "
Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setting in patients with the lung 
&#nl
The post Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(555) "
Imfinzi gave the desired result for the company through its combination with a choice of standard-of-care (SoC) chemotherapies in the first line setting in patients with the lung 
&#nl
The post Imfinzi delivers sustained OS benefit in final analysis of CASPIAN trial appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/imfinzi-os-benefit-caspian-trial/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/imfinzi-os-benefit-caspian-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8385"
  ["article_id"]=>
  string(4) "8385"
  [1]=>
  string(96) "RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration"
  ["article_title"]=>
  string(96) "RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration"
  [2]=>
  string(158) "Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the "
  ["short_description"]=>
  string(158) "Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the "
  [3]=>
  string(657) "
Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory. RIBOMIC will receive an 
&#nl
The post RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(657) "
Upon execution of this Agreement, AJU will obtain the exclusive license to develop and sell the Product containing RBM-007 (the “Product”) in the Territory. RIBOMIC will receive an 
&#nl
The post RIBOMIC enters license agreement with AJU Pharma for RBM-007 in age-related macular degeneration appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(149) "https://www.pharmaceutical-business-review.com/news/ribomic-enters-license-agreement-with-aju-pharma-for-rbm-007-in-age-related-macular-degeneration/"
  ["blog_url"]=>
  string(149) "https://www.pharmaceutical-business-review.com/news/ribomic-enters-license-agreement-with-aju-pharma-for-rbm-007-in-age-related-macular-degeneration/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "8386"
  ["article_id"]=>
  string(4) "8386"
  [1]=>
  string(74) "Merck announces top-line results from phase 3 trials evaluating Gefapixant"
  ["article_title"]=>
  string(74) "Merck announces top-line results from phase 3 trials evaluating Gefapixant"
  [2]=>
  string(155) "In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically signif"
  ["short_description"]=>
  string(155) "In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically signif"
  [3]=>
  string(612) "
In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically significant decrease in 24-hour coughs per 
&#nl
The post Merck announces top-line results from phase 3 trials evaluating Gefapixant appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(612) "
In these studies, the primary efficacy endpoints were met for the gefapixant 45 mg twice daily treatment arms – demonstrating a statistically significant decrease in 24-hour coughs per 
&#nl
The post Merck announces top-line results from phase 3 trials evaluating Gefapixant appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(127) "https://www.pharmaceutical-business-review.com/news/merck-announces-top-line-results-from-phase-3-trials-evaluating-gefapixant/"
  ["blog_url"]=>
  string(127) "https://www.pharmaceutical-business-review.com/news/merck-announces-top-line-results-from-phase-3-trials-evaluating-gefapixant/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-03-19 11:34:18"
  ["create_at"]=>
  string(19) "2020-03-19 11:34:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}